...
首页> 外文期刊>Case Reports in Nephrology and Dialysis >Oral Active Vitamin D Treatment and Mortality in Maintenance Hemodialysis Patients
【24h】

Oral Active Vitamin D Treatment and Mortality in Maintenance Hemodialysis Patients

机译:维持性血液透析患者的口服活性维生素D治疗和死亡率

获取原文
   

获取外文期刊封面封底 >>

       

摘要

>Aims: To analyze the relationship between oral active vitamin D treatment and mortality in maintenance hemodialysis (MHD) patients. Methods: We examined the association of oral calcitriol treatment with mortality in 156 MHD patients (80 men and 76 women; mean age: 59 w 15 years). The survival analysis of all-cause and cardiovascular mortality was performed using the Kaplan-Meier survival and Cox proportional-hazards analyses. Results: In all, 108 of the 156 patients received active vitamin D treatment. The intact parathyroid hormone level was obviously lower in the patients who received active vitamin D treatment than in those who did not. Throughout the whole follow-up, overall mortality was 16.7% (26 deaths, 13 in each group). The cardiovascular mortality rates were 14.6% (8/48) in the control group and 4.6% (5/108) in the calcitriol group. The crude analysis of all-cause and cardiovascular mortality using the Kaplan-Meier curve showed a significant reduction in mortality risk for patients who received oral active vitamin D compared with those who did not receive it (p = 0.015 and 0.026, respectively). Cox's regression analysis showed that active vitamin D treatment was associated with a significantly lower risk of all-cause mortality (RR = 0.399, 95% CI 0.185-0.862, p = 0.019) and cardiovascular mortality (RR = 0.295, 95% CI 0.094-0.93, p = 0.037). However, after adjusting for potential confounding variables, oral active vitamin D therapy was no longer clearly associated with a lower risk of either all-cause or cardiovascular mortality. Conclusion: Oral active vitamin D treatment was associated with improved survival in MHD patients. However, this survival benefit was smaller than previously reported, and a large cohort study should be performed. i 2014 S. Karger AG, Basel
机译:> 目标: 目的分析口服活性维生素D治疗与维持性血液透析(MHD)患者死亡率之间的关系。 方法: 我们研究了156名MHD患者(80名男性和76名女性;平均年龄:59岁至15岁)中口服骨化三醇治疗与死亡率的相关性。使用Kaplan-Meier生存率和Cox比例风险分析对全因和心血管死亡率进行生存率分析。 结果: 总共156名患者中有108名接受了有效的维生素D治疗。接受活性维生素D治疗的患者的完整甲状旁腺激素水平明显低于未接受维生素D治疗的患者。在整个随访过程中,总死亡率为16.7%(26例死亡,每组13例)。对照组的心血管死亡率为14.6%(8/48),而骨化三醇组的心血管死亡率为4.6%(5/108)。使用Kaplan-Meier曲线对全因和心血管死亡率进行的粗略分析显示,与未接受口服活性维生素D的患者相比,接受口服活性维生素D的患者的死亡风险显着降低(分别为p = 0.015和0.026)。 Cox回归分析显示,积极的维生素D治疗与全因死亡率(RR = 0.399,95%CI 0.185-0.862,p = 0.019)和心血管死亡率(RR = 0.295,95%CI 0.094- 0.93,p = 0.037)。然而,在对潜在的混杂变量进行调整之后,口服活性维生素D治疗不再明显与全因或心血管死亡的较低风险相关。 结论: 口服活性维生素D治疗与MHD患者的生存改善有关。但是,这种生存获益比以前报道的要小,应该进行大型队列研究。在2014 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号